Best Japanese Companies To Buy Right Now

Best Japanese Companies To Buy Right Now: AcelRx Pharmaceuticals Inc.(ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain in the United States. The company develops ARX-01, a Sufentanil NanoTab PCA system, which completed Phase II clinical trial for acute post-operative pain. The Sufentanil NanoTab PCA system consists of sufentanil, a high therapeutic index opioid; NanoTabs, a non-invasive sublingual dosage form; and a handheld PCA device that enables simple patient-controlled delivery of NanoTabs in the hospital setting and eliminates the risk of programming errors. Its products also include ARX-02, a Sufentanil NanoTab BTP Management System that completed Phase II clinical trial for the treatment of cancer breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which completed Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a ph ysician?s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood, California.

Advisors' Opinion:

• [By Sean Williams]

  AcelRx Pharmaceuticals (NASDAQ: ACRX  ) received a nice boost from Jefferies this week, after an analyst there initiated coverage on the company with a "buy" rating and a price target of $8, implying about 33% upside from Friday's close. The covering analyst, Corey Davis, is forecasting that AcelRx's post-operative pain management drug/system, sufentanil NanoTab PCA -- which allows patients to give themselves a pre-set dose of sufentanil under their tongue instead of intravenously -- will be approved by the FDA in 2014 and become up to a $400 million dru! g in the United States. AcelRx's delivery system does drastically reduce the potential for infections and dosing errors, but I always remain concerned when pain medication systems go before the FDA. In essence, I'd still tread cautiously around this story.

• [By Sean Williams]

  The good
  Heralding the charge higher was AcelRx Pharmaceuticals (NASDAQ: ACRX  ) which advanced 18% on the week after disclosing on Tuesday that its post-operative pain management system, Sufentanil NanoTab PCA, met its primary endpoint in late-stage trials and reconfirmed all previous late-stage study results. This data is strong enough for AcelRx to seek approval from the Food and Drug Administration with a new drug application filing expected next quarter. I'd be cautious with AcelRx moving forward, as the possibility of an FDA rejection for opioid-based treatments is always a possibility.

• [By Eric Volkman]

  AcelRx (NASDAQ: ACRX  ) is going to market for a fresh round of funding. The company announced it will float shares of its common stock in an underwritten public flotation. Additionally, the firm expects to grant the issue's underwriters a 30-day purchase option for up to an additional 15% of the total amount of the shares in the offering.

source from Top Stocks For 2015:http://www.topstocksblog.com/best-japanese-companies-to-buy-right-now.html